Red Light Therapy for MS
Multiple sclerosis rates have quadrupled since the 1990s—a rise too rapid to be explained by genetics alone. MS is also concentrated geographically in the same regions where Lyme disease is endemic: the Northeast, Upper Midwest, and similar temperate climates worldwide. These patterns have led a growing number of researchers and clinicians to question whether some MS diagnoses involve underlying infectious or inflammatory triggers that haven't been fully explored.
Regardless of what initiates MS, the cellular damage is consistent: chronic neuroinflammation, disrupted myelin integrity, impaired mitochondrial function in neurons, and restricted cerebral blood flow. Red light therapy—particularly near-infrared wavelengths that reach neural tissue—addresses these mechanisms directly. This guide covers what the evidence suggests and how photobiomodulation fits into a comprehensive MS support protocol.
Quick Answer
Red light therapy may support multiple sclerosis by reducing neuroinflammation, stimulating mitochondrial energy production in neurons, supporting myelin repair processes, and improving cerebral blood flow. Near-infrared wavelengths (810–850nm) can penetrate to neural tissue through the skull, making transcranial photobiomodulation relevant for the neurological component of MS. When combined with EWOT as the Oxygen Synergy System, it addresses both the oxygen delivery and the cellular utilization aspects of MS-related neurological dysfunction.
MS, Lyme, and the Diagnostic Overlap Worth Knowing About
MS cases in the United States have more than quadrupled since the 1990s. That rate of increase doesn't fit a genetic disease—genes don't change that quickly. Something environmental is clearly driving the rise, and researchers have been searching for answers. One hypothesis that has gained significant traction is the infectious trigger model: that MS may, in at least some cases, be initiated or mimicked by infections including Epstein-Barr virus (EBV) and Borrelia burgdorferi, the bacterium that causes Lyme disease.
The geographic overlap is striking. MS prevalence is highest in the Northeast, Upper Midwest, Pacific Northwest, and Great Lakes region of the United States—exactly the regions where Lyme disease is most endemic. In Europe, the same pattern holds: high MS prevalence correlates with high Lyme exposure. This is not proof of causation, but it's a pattern that researchers are taking seriously.
More concerning: studies suggest that approximately 1 in 5 MS diagnoses may be incorrect. Lyme disease is a known MS mimic—it can produce identical MRI lesions, identical neurological symptoms, and identical relapsing-remitting patterns. The diagnostic criteria for MS does not require ruling out Lyme infection, and standard Lyme tests have well-documented sensitivity limitations. Patients who have Lyme-induced neurological disease may receive an MS diagnosis and be placed on immunosuppressant therapies that can worsen outcomes if an active infection is present.
This is not medical advice, and most people with MS do have MS. But given the geographic overlap, the diagnostic ambiguity, and the 20% misdiagnosis rate documented in the literature, it may be worth asking your neurologist whether Lyme disease testing has been done. Both MS and Lyme respond to interventions that reduce inflammation and restore cellular energy—but active bacterial infection also warrants appropriate antimicrobial treatment. See also: EWOT for Lyme disease
How MS Damages Cells and Energy Production
Whether MS is initiated by an autoimmune process, an infectious trigger, or a combination, the downstream cellular damage follows a consistent pattern. Chronic neuroinflammation disrupts the blood-brain barrier, activates microglia, and damages oligodendrocytes—the cells responsible for producing and maintaining myelin, the protective sheath around nerve fibers.
Demyelination slows or blocks nerve signal transmission and exposes underlying axons to damage. But the energy crisis that accompanies MS is equally significant. Demyelinated axons require far more energy to transmit signals than myelinated ones—but the same neuroinflammation that destroys myelin also restricts cerebral blood flow and impairs mitochondrial function, leaving neurons with less energy precisely when they need more. This energy-demand mismatch contributes to MS fatigue, cognitive dysfunction, and the progressive neurological decline that characterizes the condition over time.
Red Light Therapy Mechanisms for MS
Photobiomodulation engages several mechanisms that are directly relevant to MS pathophysiology. Rather than targeting any single aspect of the condition, red light therapy works across multiple overlapping systems simultaneously.
Mitochondrial Energy Restoration in Neurons
The stimulation of cytochrome c oxidase—the primary mechanism of red light therapy—directly increases ATP production in neurons. For MS patients whose neurons are struggling to maintain signal transmission through damaged myelin on an energy-depleted budget, mitochondrial stimulation may provide meaningful support for neurological function.
Neuroinflammation Reduction
Red and near-infrared light reduces production of pro-inflammatory cytokines and decreases microglial over-activation—the same inflammatory processes that drive demyelination and neuronal damage in MS. By reducing the neuroinflammatory load, photobiomodulation may help slow the progression of tissue damage and support the cellular environment needed for repair.
Improved Cerebral Blood Flow
Near-infrared light stimulates nitric oxide production and promotes vasodilation in cerebral blood vessels. Research has demonstrated measurable increases in cerebral perfusion following transcranial photobiomodulation sessions. For MS patients, improved cerebral blood flow means more oxygen and nutrients delivered to energy-starved neurons and oligodendrocytes.
Blood-Brain Barrier Support
Emerging research suggests that photobiomodulation may help restore blood-brain barrier integrity, which is often disrupted in MS. A more intact blood-brain barrier means less inflammatory infiltration from peripheral immune cells into neural tissue—reducing ongoing neuroinflammatory damage.
Myelin Support and Neuroprotection
Myelin repair (remyelination) is one of the most energy-intensive processes in the nervous system. Oligodendrocytes must synthesize large quantities of myelin-specific proteins and lipids to rebuild damaged sheaths—a process that requires massive ATP investment. When the neurological energy deficit of MS leaves oligodendrocytes chronically under-powered, remyelination is impaired even when the oligodendrocytes themselves survive.
Red light therapy may support remyelination indirectly by restoring the cellular energy environment that makes it possible: reducing neuroinflammation, improving mitochondrial function, and supporting cerebral blood flow. Some animal research has shown improved myelination markers following photobiomodulation, though human clinical data specifically in MS patients remains limited.
Neuroprotection: Preserving What's Left
Even when the primary goal is slowing progression rather than reversing damage, neuroprotection is valuable. By reducing oxidative stress, decreasing neuroinflammation, and improving cellular energy, photobiomodulation may help preserve axonal integrity in areas where demyelination hasn't yet occurred—potentially slowing the rate at which new lesions develop and reducing the accumulation of disability over time.
The Oxygen Synergy Protocol for Neurological Conditions
For MS patients, the Oxygen Synergy System—EWOT followed immediately by red light therapy—offers a protocol that addresses both the oxygen delivery and cellular utilization aspects of neurological energy deficit.
EWOT (Exercise with Oxygen Therapy) floods the body with high-concentration oxygen during mild exercise. For MS patients, the exercise component should be calibrated to current ability—even gentle stationary cycling or slow walking is sufficient to trigger the cardiovascular responses (vasodilation, increased blood pressure and velocity, capillary recruitment) that push oxygen into tissue. The high-concentration oxygen then dissolves directly into blood plasma via Henry's Law, reaching cerebral tissue and hypoxic neurons.
Step 1 — EWOT: 10–15 minutes of mild exercise breathing 93%+ oxygen. Pace to comfort—MS patients should not push into fatigue. Even gentle movement is sufficient to drive the physiological oxygen delivery mechanisms.
Step 2 — Red Light: 7–10 minutes immediately after EWOT. Direct near-infrared light at the head, neck, and upper torso. Use goggles. The mitochondria are primed from EWOT; the shorter red light session achieves the same stimulatory result.
Frequency: 3–5x per week. Allow rest days as needed based on symptom load and energy availability.
How to Use Red Light Therapy for MS
For MS-specific neurological support, near-infrared wavelengths are the priority. Position the panel at head height, 6–12 inches from the face and scalp, for 10–15 minutes per session. Always wear the included protective goggles when directing the panel toward the head. Full-body sessions also provide systemic anti-inflammatory benefits—treating the entire torso in the same session reduces the total inflammatory burden contributing to neurological symptoms.
Managing MS Fatigue During Sessions
MS fatigue is a distinct symptom driven by neurological dysfunction, not simply physical tiredness. Red light therapy is passive and non-demanding, making it well-suited for MS patients. Sessions can be done lying down with the panel positioned above. There's no minimum activity level required—the photobiomodulation response occurs regardless of the patient's physical state.
Tracking Symptoms
Track fatigue levels (1–10 scale), cognitive clarity, mobility and coordination, sleep quality, and any relapse activity over time. MS symptom tracking is valuable both for monitoring response to any supportive therapy and for communicating changes to your neurologist.
Red light therapy is a supportive wellness practice and is not intended to diagnose, treat, cure, or prevent multiple sclerosis or any other medical condition. Individuals with MS should continue working with their neurologist and should not alter prescribed disease-modifying therapies without medical guidance.
Catalyst Red Light Panels
Deep NIR Wavelengths for Neurological Support
8 wavelengths from 630–1060nm. Dual-chip LEDs. Goggles included. Free shipping.
Frequently Asked Questions
Can red light therapy help with multiple sclerosis?
Research suggests red light therapy may support MS by reducing neuroinflammation, stimulating mitochondrial energy production in neurons, improving cerebral blood flow, and potentially supporting the cellular environment needed for myelin repair. It is not a disease-modifying treatment and should not replace prescribed MS therapies, but many MS patients use it as a supportive tool alongside their medical care.
Is Lyme disease related to multiple sclerosis?
Research indicates that Lyme disease can produce MS-like symptoms, identical MRI lesions, and similar relapsing-remitting neurological patterns—leading some neurologists to refer to Lyme as an "MS mimic." Studies suggest approximately 1 in 5 MS diagnoses may be incorrect, and Lyme disease is among the most common misdiagnosis causes. The geographic distribution of MS and Lyme disease also overlaps significantly, particularly in the Northeast and Upper Midwest.
What wavelengths of red light are best for MS?
Near-infrared wavelengths (810nm, 830nm, 850nm) are most relevant for MS because they penetrate deeply enough to reach neural tissue and cross the blood-brain barrier. These wavelengths stimulate mitochondria in neurons and oligodendrocytes, reduce neuroinflammation, and improve cerebral blood flow. Full-spectrum panels that include both red (630–670nm) and near-infrared provide the most comprehensive coverage.
Can people with MS do EWOT?
Many people with MS can do EWOT, particularly those who retain significant mobility. The key is calibrating exercise intensity to current ability—even very gentle stationary cycling is sufficient to trigger the physiological oxygen delivery mechanisms. MS patients should consult their neurologist before beginning EWOT, particularly those with significant disability, balance issues, or heat sensitivity.
How often should people with MS do red light therapy?
Daily or near-daily sessions are appropriate for most MS patients doing red light therapy. Neurological changes are cumulative and slow—consistency over months matters more than any single session. For combined EWOT + red light sessions, 3–5x per week is a practical frequency that allows for adequate recovery.
Next Step
Explore red light therapy panels for home use
Targeted, mid-range, and full-body options. Same core technology, different coverage areas.